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Abstract
Purpose—Clinical trials in early breast cancer have suggested that benefits of adjuvant bone
targeted treatments are restricted to women with established menopause. We developed models
that mimic pre- and post-menopausal status to investigate effects of altered bone turnover on
growth of disseminated breast tumour cells. Here we report a differential anti-tumour effect of
zoledronic acid (ZOL) in these two settings.
Experimental design—12-week old female Balb/c-nude mice with disseminated MDA-
MB-231 breast tumour cells in bone underwent sham operation or ovariectomy (OVX), mimicking
the pre- and post-menopausal bone microenvironment, respectively. To determine the effects of
bone-targeted therapy, sham/OVX animals received saline or 100ug/kg ZOL weekly. Tumour
growth was assessed by in vivo imaging and effects on bone by RT-PCR, microCT,
histomorphometry and measurements of bone markers. Disseminated tumour cells were detected
by two-photon microscopy.
Results—OVX increased bone resorption and induced growth of disseminated tumour cells in
bone. Tumours were detected in 83% of animals following OVX (post-menopausal model)
compared to 17% following sham operation (pre-menopausal model). OVX had no effect on
tumours outside of bone. OVX-induced tumour growth was completely prevented by ZOL, despite
the presence of disseminated tumour cells. ZOL did not affect tumour growth in bone in the sham-
operated animals. ZOL increased bone volume in both groups.
Conclusions—This is the first demonstration that tumour growth is driven by osteoclast-
mediated mechanisms in models that mimic post-but not pre-menopausal bone, providing a
biological rationale for the differential anti-tumour effects of ZOL reported in these settings.
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Introduction
There is increasing evidence of differential therapeutic effects of bone-sparing agents in the
pre- and post-menopausal setting from clinical trials in breast cancer, with benefits largely
confined to women with established menopause (1-3). These results indicate that the
mechanisms that govern breast cancer progression, and also the response to therapeutic
intervention, are influenced by the endocrine status of the patient. The first indication that
menopausal status was important in determining the response to anti-resorptive agents came
from the AZURE (Does Adjuvant Zoledronic acid redUce REcurrence in stage II/III breast
cancer?) trial (1). In AZURE, 3,360 women at high risk of breast cancer recurrence were
randomised to receive either placebo or intensive treatment with zoledronic acid (ZOL), in
addition to standard therapy, and the primary endpoint was diseases-free survival (DFS).
The initial analysis that included the entire study population showed no overall increase in
DFS following zoledronic acid treatment. However, sub-group analysis demonstrated that
women who were postmenopausal for at least 5 years before study entry had a significantly
reduced risk of DFS (25%) and the risk of death from any cause was reduced by 26%.
Similar differential effects between pre- and post-menopausal patient populations have
subsequently been reported from other trials, including NSABP-B34 (increased DFS in
women over age 50 receiving clodronate) (2) and ABCSG-12 (increased survival in women
over age 40 who receive zoledronic acid) (3). Surprisingly, these bone-targeted agents also
reduced the risk of extra-skeletal recurrence, indicating that modifying the bone
microenvironment affects subsequent tumour progression in distant sites.
During metastasis, the spread of breast tumour cells from the primary site to specific niches
in the bone marrow is generally accepted to be an early event, and metastases may originate
from these disseminated tumour cells. Once established in putative metastatic niches in
bone, tumour cells can remain dormant for several years under the control of environmental
cues, and in many cases never develop into clinically overt metastasis (4,5). During this
period there is a close association between tumour cells and the main cell types of the bone
microenvironment, bone forming osteoblast and bone resorbing osteoclasts (6). Eventually,
yet to be identified events trigger the escape of tumour cells from dormancy, and initiate
tumour progression and the development of overt bone metastasis. Modification of the bone
microenvironment has been shown to affect the levels of tumour cell colonisation (7).
Evidence from model systems demonstrated that expansion of the osteoblast niche by
administration of parathyroid hormone (PTH) increased subsequent colonisation of bone by
prostate cancer cells (7). The osteoclast is also key to tumour progression in bone, as pre-
treatment with anti-resorptive agents inhibits subsequent breast tumour growth in bone and
delays the progression of established tumours (8). To optimise tumour engraftment, the
majority of xenograft models of bone metastasis use young animals (5-6 week old) with an
immature skeleton and rapid bone remodelling, supporting the notion that increased
osteoclast activity and/or bone turnover facilitates skeletal tumour cell colonisation and
Ottewell et al. Page 2
Clin Cancer Res. Author manuscript; available in PMC 2014 December 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
progression. In agreement with this, studies from model systems have demonstrated that
anti-resorptive agents (mainly zoledronic acid) also inhibit development of bone metastasis
in young animals (9). However, the majority of patients who develop breast cancer bone
metastasis will have undergone menopause, and for this group the clinical relevance of data
obtained using standard xenograft models is limited. This study is the first to establish how
breast tumour cells grow bone in models that mimic the pre- and post-menopausal bone
microenvironment, and to demonstrate that the potent anti-resorptive agent zoledronic acid
differentially modifies tumour growth in these two settings.
Materials and Methods
Cell Culture
Low passage (< P10) human breast cancer cells, MDA-MB-231-luc2 tdTomato
(authenticated and purchased from Caliper Lifer Sciences, Cheshire, UK) or MDA-MB-231
(European Collection of Cell Cultures, Wiltshire, UK) transfected with eGFP were used.
Prior to in vivo inoculation eGFP expressing cells were incubated for 15 minutes with 25μM
of 1,1′-Dioctadecyl-′, 3′-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate (DiD)
(Life Technologies, Paisley, UK). Tumour growth was monitored using an IVIS (luminol)
system (Caliper Life Sciences) (luc2) or an Illumatool Lighting System (LightTools
Research, Encintas, CA) (eGFP).
In vivo studies
We used 12-week-old female Balb/c nude mice (Charles River, Kent, UK). Experiments
were carried out in accordance with local guidelines and with Home Office approval under
project licence 40/3462, University of Sheffield, UK.
Following ovariectomy (OVX) or sham operation animals were sacrificed 1-8 weeks later
(n=5/group) and bone effects assessed. Effects of OVX on tumour cell homing and
colonisation of bone were established by OVX/sham operating mice 7 days before tumour
cell inoculation (n=10/group). For studies of bone homing and colonisation mice were culled
24h and 8 weeks after tumour cell injection, respectively. Effects of OVX on disseminated
tumour cells were assessed following injection of breast cancer cells 7 days before OVX,
sham, or non-operation (n=10/group) in ER+ve and ER-ve cell lines. 1×105 DiD labelled
MDA-MB-231-luc-2 tdTomato cells were injected into the left cardiac ventricle (i.c.),
tumour growth was monitored for 8 weeks. 0.1mls saline or 1×105 MCF7 cells were injected
i.c. 4 days following sham or implantation of 17β estradiol pellet (innovative Research of
America). Effects of estradiol alone were assessed at 4 weeks and tumour growth monitored
for 10 weeks.
Effects of ZOL on OVX-induced tumour growth were investigated in mice inoculated with
1×105 DiD labelled MDA-MB-231-eGFP cells i.c., and given weekly ZOL (100 μg/kg) or
saline (n=20/group) from day 5. Seven days following tumour cell inoculation, animals from
both groups underwent either sham or OVX (n=10). Assessment of PTH on tumour growth
was investigated in mice inoculated with 1×105 MDA-MB-231-luc-2 tdTomato cells i.c.,
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and given PTH (80μg/kg) or saline daily for 5 days (n=10/group) and animals sacrificed at 5
weeks.
Serum was stored at −80°C for ELISA, tibiae and femurs were fixed in 4% PFA for μCT
analysis before decalcification in 1%PFA/0.5% EDTA and processing for histology. Bones
for two-photon analysis were stored in OCT at −80°C.
Microcomputed tomograpgy imaging
Microcomputed tomography analysis was carried out using a Skyscan 1172 x-ray-computed
microtomography scanner (Skyscan, Aartselaar, Belgium) equipped with an x-ray tube
(voltage, 49kV; current, 200uA) and a 0.5-mm aluminium filter. Pixel size was set to 5.86
μm and scanning initiated from the top of the proximal tibia as previously described (10).
Bone histology and measurement of tumour volume
Osteoclasts were detected by toluidine blue and tartate-resistant acid phosphatase (TRACP)
staining as previously described (11). Osteoblasts were identified as mononuclear, cuboidal
cells residing in chains along the bone surface. The number of osteoclasts/osteoblasts per
millimeter of cortical-endosteal bone surface and trabecular bone surfaces and the
proportion of bone surface occupied by osteoclasts/osteoblasts was determined using a Leica
RMRB upright microscope and OsteoMeasure software (Osteometrics inc.) as previously
described (12).
Two-photon microscopy
Tibiae were imaged using a multiphoton confocal microscope (LSM510 NLO upright;
Zeiss, Cambridge, UK). DiD labelled cells were visualised using a 900nm Chameleon laser,
bone was detected using the 633nm multiphoton laser (Coherent, Santa Clara, CA.) and
images were reconstructed in LSM software version 4.2 (Zeiss).
Biochemical analysis
Serum concentrations of TRACP 5b, P1NP and PTH were measured using commercially
available ELISA kits: MouseTRAP™ Assay (Immunodiagnostic systems), Rat/Mouse P1NP
competitive immunoassay kit (Immunodiagnostic Systems) and Mouse PTH (Uscn Life
Sciences), respectively
Real-time PCR
Gene expression was analysed on 3 custom-made microarray plates (Ref: 0186817032) per
group (all reagents from Applied Biosystems, Warrington UK): Relative mRNA expression
compared with the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Hs99999905_m1) was assessed using an ABI 7900 PCR System (Perkin Elmer,
Foster City, CA) and Taqman universal master mix). Fold change in gene expression
between treatment groups was assessed by directly inserting CT values into Data Assist
V3.01 software (Applied Biosystems) and changes in gene expression were only analysed
for genes with a CT value of ≤25.
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Statistical Analysis
Statistical analysis was by one way analysis of variance (ANOVA) followed by Newman-
Keuls multiple comparison test. Statistical significance was defined as P less than or equal to
0.05. All P values are two-sided.
Results
Characterisation of ovariectomy-induced changes in the bone microenvironment
A longitudinal study was performed to establish how OVX modified the bone
microenvironment in Balb/c nude mice (figure 1). Ovariectomised animals had significantly
reduced trabecular bone volume by week two, compared to sham operated animals (p<0.01),
associated with an initial increase in the serum levels of the osteoclast marker TRACP, and
corresponding decrease in the osteoblast activity marker P1NP. There was no significant
difference in either osteoblast or osteoclast numbers between sham and OVX animals at any
time point. In subsequent experiments tumour cells were inoculated seven days following
OVX for tumour cell colonisation to coincide with bone loss. The bone microenvironment
following sham or OVX was considered to model the pre- and post-menopausal setting,
respectively.
Effects of ovariectomy on homing of breast tumour cells and colonisation of bone
Tumour growth in bone was investigated following i.c. injection of MDA-MB-231 breast
cancer cells in female mice. In pilot studies, 90% of 6-week old animals had detectable
skeletal tumour growth following this protocol (supplementary figure 1), compared to only
20% of 12-week old animals, a difference attributed to the higher rate of bone turnover in
young animals.
We investigated whether the OVX-induced changes to the bone microenvironment modified
the ability of breast cancer cells to home to and colonise bone. MDA-MB-231 cells were
injected into 12-week old mice 7 days after OVX or sham operation. 24h after tumour cell
injection flow cytometric analysis of cells flushed from the marrow cavity of long bones
showed significantly higher numbers of tumour cells in control mice compared with OVX
animals (427.7 ± 87.6 tumour cells/1×106 mononuclear in control v.s. 150.7 ± 23.17 in
OVX mice (P<0.005) (supplementary figure 2a), implying that OVX decreases the initial
number of tumour cells that home to the bone microenvironment. Multiphoton analysis of
the bones confirmed these results (supplementary fig 2b). 48 days following tumour cell
injection tumour growth in bone was detected in 17% of control and 18% of sham operated
animals, compared to 89% of animals that had undergone OVX (p<0.001 for OVX vs.
control or sham, figure 2). Number and size of tumours in the long bones were increased
following OVX, with 1.67 ± 0.41 tumours detected per mouse with an average BIL of
1.09×106 ± 0.09×106 photons per second (p/s) following OVX compared with 0.43 ± 0.12
tumours with an average BIL of 0.23×106 ± 0.08×106 p/s following sham operation
(P<0.001). Tumour burden in non-bone sites was similar in all groups (18% in OVX, 17% in
control and 18% in sham). OVX induced the expected reduction in bone volume compared
to sham/control (BV/TV = 9.11 ± 0.32% in OVX, 13.85 ± 0.23% in control and 14.07 ±
0.13% in sham; p<0.001 for OVX vs. control or sham), supporting that modification of the
Ottewell et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2014 December 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
bone microenvironment is associated with increased tumour cell colonisation and/or ability
of tumour cells to form overt colonies.
Effects of ovariectomy on growth of disseminated breast tumour cells in bone
Following i.c. implantation of MDA-MB-231 cells in 12-week old animals, the majority of
tumour cells that reach bone die within 72h, leaving behind a small number of disseminated
tumour cells that do not form overt colonies. We investigated whether modifying the bone
microenvironment through OVX affects the ability of these disseminated tumour cells to
form colonies. OVX performed seven days following tumour cell injection resulted in a
substantial increase in tumour growth in bone, accompanied by a 34% and 36% loss in
trabecular bone compared to the sham or control group respectively (P<0.001) (figure 3). 89
% of animals that had undergone OVX developed tumours in bone, compared to 17% of the
animals in the control and 11% in the sham group (P<0.001 for OVX vs. control or sham).
Compared to the sham group, animals in the OVX group had both increased number (2.55 ±
0.86 tumours per long bone vs. 0.46 ± 0.32) and larger tumours (1.35×106 ± 0.02 p/s vs.
0.02 ± 0.01 p/s). The OVX-induced increase in tumour growth was specific to bone, with
extra-skeletal tumours detected in 18% of OVX, 17% of control and 18% of sham operated
animals.
Differential effects of osteoclast inhibition on tumour growth in bone in the pre- and post-
menopausal setting
We investigated whether tumour growth in bone was driven by increased bone resorption by
treating sham and OVX animals with the potent osteoclast inhibitor ZOL. MDA-MB-231
cells were injected i.c. in two groups of animals that received weekly injections of saline
(control, n=20) or ZOL (100ug/kg, n=20) for 4 weeks. Half of the animals from each group
subsequently underwent either a sham operation or OVX on day 7 (n=10/group) and tumour
growth was monitored until day 35. 86% animals that underwent OVX had detectable
tumours in bone compared to 33% of sham (P<0.001), supporting that increased bone
resorption stimulated tumour growth in the post-menopausal setting (figure 4). There was a
significant reduction of tumour growth in bone in OVX animals treated with ZOL (17%)
compared to OVX control (86%) (P<0.001). In contrast, ZOL treatment did not affect
skeletal tumour growth in the sham group, with 33% of both control and ZOL treated sham
operated animals having detectable tumours in bone. Despite the differential effects on
tumour growth, ZOL caused a significant increase in bone volume in both OVX and sham
operated animals compared to the respective controls (figure 4 c-d). Bone volume/trabecular
volume increased from 12.91 ± 1.25% in sham OVX to 17.21 ± 1.15% in sham ZOL
(p<0.01) and from 10.52 ± 1.29% in OVX control compared with 16.25 ± 1.37% (P<0.01),
no significant differences in bone volume were detected between sham or OVX animals
treated with ZOL, demonstrating that bone resorption is reduced to the same extent in
models of pre- and post-menopausal bone.
Multiphoton microscopy confirmed the presence of individual MDA-MB-231 cells in the
long bones of animals that had not developed overt bone tumours on day 35 regardless of
group, demonstrating that the tumour cells successfully engrafted in bone but remained non-
proliferative for extensive periods in all settings (figure 5).
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OVX-induced gene expression changes in the bone microenvironment are modified by
ZOL
We compared the expression of a panel of genes using long bones isolated from control and
ZOL treated animals seven days following OVX or sham operation. The genes were selected
based on reported roles in bone turnover and/or tumour growth in bone, as well as stem cell
mobilisation. Table 1 shows the genes for which a more than two-fold change in expression
levels between OVX and sham was detected. A full gene list is given in supplementary table
2. As expected, OVX induced expression of a number of genes associated with increased
bone resorption (including Cathepsin K, TRAP, MMP9, RANKL and PTH), which was
inhibited by treatment with ZOL. There was a significant change in genes affecting bone
formation following OVX (including reduced expression of the osteoblast formation
inhibitors Dkk1, 2 and 3), and this was reversed in the ZOL treated animals. ZOL modified
expression genes linked to bone turnover in both the sham and OVX animals, in agreement
with the ability of ZOL to inhibit bone loss in both groups (figure 4). Interestingly, ZOL
differentially modified genes associated with stem cell mobilisation in sham and OVX
animals.
Effects of PTH on MDA-MB-231 tumour growth in bone
Molecular analysis of bones from OVX operated animals showed a significant increase in
PTH expression compared with sham operated animals, which was reversed by treatment
with ZOL. Analysis of serum from OVX and sham operated animals by ELISA showed a
trend towards increased levels of PTH following OVX (12.82 ± 1.12 pg/ml) compared with
control (16.31 ± 1.25) although this did not reach significance (P = 0.055, data not shown).
We therefore investigated the effects of PTH on tumour growth in bone. Administration of
80μg/kg rhPTH for 5 days resulted in a 29% increase in TRAP levels reflecting elevated
osteoclast activity, accompanied by an increase in tumours from 0.6/mouse in control to
2.14/mouse in PTH treated animals (supplementary figure 3a and b). These data demonstrate
a correlation between increased bone resorption and tumour growth in bone, similar to those
obtained following OVX.
Discussion
Using experimental systems that separately model the pre- and post-menopausal bone
microenvironment, combined with advanced imaging of disseminated tumour cells in bone,
we have identified major differences in tumour growth and response to anti-resorptive
therapy. Breast cancer cells homed to the long bones following intra-cardiac inoculation in
12-week old mice, but failed to progress to form overt tumours in the majority of animals
unless preceded by OVX (Figure 2). OVX also induced the growth of disseminated tumour
cells in bone, whereas a sham operation did not (Figure 3). We used the established
oestrogen-independent MDA-MB-231 cells, as oestrogen-dependent MCF7 cells did not
form bone metastasis following i.c. injection 10 weeks after implantation (data not shown).
Oestrogen supplementation caused major changes to the bone volume structure significantly
altering the bone microenvironment and hence was unsuitable for our studies
(supplementary figure 4).
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A limitation of our study is the differences in bone turnover rates in mice and humans, with
changes to the bone microenvironment following OVX manifesting themselves within a few
days in mice. These rapid changes may affect the growth of resident tumour cells to a higher
degree than would be the case in humans. However, as early stages of tumour cell
colonisation of bone cannot be studied in patients, model systems continue to provide
valuable information relating to initiation of bone metastasis. ZOL specifically inhibited
OVX-induced bone tumour growth, supporting the observed benefit of anti-resorptive
therapy in post-menopausal breast cancer patients (1, 3). In contrast, no effect on tumour
growth in bone was seen in sham operated animals, reflecting the lack of benefit of adjuvant
ZOL in the pre-menopausal breast cancer patients (1, 13). Our results provide new insights
into the mechanisms driving tumour growth in bone that may contribute to differential
therapeutic effects of ZOL in the pre-and post-menopausal setting.
We present two major findings; firstly, that OVX-induced changes to the bone
microenvironment can trigger growth of disseminated breast tumour cells, and secondly, that
these changes are completely abolished by ZOL and hence mediated by osteoclast activity.
Our data support that tumour cells remain quiescent in the mature skeleton until they receive
microenvironmental signals that stimulate their proliferation. Tumour cells that persist in
bone are thought to occupy specific niches identical to, the hematopoietic stem cell (HSC)
niche (7). Tumour proliferation in bone may therefore be regulated by many of the same
processes that control HSC mobilisation and quiescence, including osteoblast and osteoclast
activities (14-16). Although not clearly defined, the “bone metastatic niche” maybe located
at endosteal bone surfaces in the long bones. In agreement, the single tumour cells we
detected in bone were closely associated with endosteal surfaces of trabecular bone in
proximity to the growth plate (figure 5).
There is accumulating evidence that osteoclasts are central to mobilisation of HSCs, mainly
through the production of proteolytic enzymes that disrupt SDF-1-CXCR4 interactions (14).
Increased bone resorption following administration of RANKL stimulates egress of HSCs
from bone marrow niches into the circulation, disrupts the adhesion of HSCs and niche
components that maintain cell quiescence resulting in proliferation (17). Other ‘stress’
signals in the endosteal niche, e.g. OVX-induced bone loss, may have similar effects.
Remodelling of the extracellular matrix during bone resorption may also disrupt integrin
interactions that maintain tumour cells in a state of quiescence (18).
Previous studies addressing the long-term skeletal effects of OVX in mouse models, show
significant bone loss persisting for several weeks (19-20). To capture the events associated
with induction of disseminated tumour cell proliferation, we investigated the molecular and
cellular changes to the bone microenvironment seven days after OVX/sham operations. At
this point, a range of genetic changes reflecting increased bone resorption and/or reduced
bone formation were detectable (table 1). OVX induced a significant increase in expression
of RANKL, a stimulator of osteoclast formation and activity (21), coupled with decreased
expression of the RANKL inhibitor osteoprotegerin (22). In addition, Dkk-1, an inhibitor of
osteoblast differentiation was increased (23). OVX also caused increased expression of
proteolytic enzymes associated with elevated osteoclast activity, including MMP-9 and
Cathepsin K (24). In addition to the established roles in bone turnover, these molecules also
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activate the bone marrow endosteal stem cell niche and stimulate mobilisation of
vasculogenic progenitors (25). MMP9 plays a critical role in mobilisation of hematopoietic
and endothelial precursor cells from the bone marrow niche through cleaving of membrane
KitL to its soluble form, a key component of the osteoblast stem cell niche essential for
endosteal lodging of murine stem cells (24). Interestingly, c-KitL was the gene most
upregulated following OVX. It is possible that changes in the levels of cKitL may also affect
the mobilisation of tumour cells that reside in the niche. We hypothesise that the non-
proliferating tumour cells present in the bone marrow prior to OVX are the cells that have
the capacity to form tumours and hence have stem cell like properties, and modification of
the bone microenvironment mediates mobilisation of these cells from bone marrow niches
and initiate tumour growth. Importantly, the increased tumour growth following OVX was
not a result of increased numbers of tumour cells homing to bone compared to sham
(supplementary figure 2).
We used the anti-resorptive agent, ZOL, to establish whether OVX-induced tumour growth
was triggered by increased osteoclast activity. ZOL increased bone volume to the same
extent in animals that had undergone either sham or OVX, reflected by changes in bone
gene expression levels. These results are in agreement with clinical studies showing that
ZOL decreases the level of bone resorption markers in both pre- and post-menopausal
women (1, 13). However, we found major differences in the ability of ZOL to modify
tumour growth in bone. In the sham group, mimicking the pre-menopausal setting, ZOL had
no effect on the growth of skeletal tumours (figure 4). In contrast, ZOL completely
prevented OVX-induced tumour growth in bone (mimicking the post-menopausal setting).
Only four genes (KitL, Igf1, Igf2 and MmP14) in our panel were differentially affected by
ZOL in the OVX vs. the sham group, all of which are associated with regulating stem cell
niches (26-28). Further studies are required to establish the role of these changes in initiation
of bone metastasis. Tumour growth outside the skeleton (including lung) was not affected by
ZOL treatment in either group, but the models do not capture metastasis to extra-skeletal
sites that may occur during subsequent tumour progression. We have previously shown that
administration of 100ug/kg ZOL weekly for 6 weeks does not induce tumour cell apoptosis
in a bone metastasis model, hence ZOL does not reduce tumour growth by direct tumour cell
toxicity (29). There are clear limitations to mimicking effects of menopause in mice, in
particular the role of the changes in circulating hormones. However, our results clearly
indicate that breast tumour progression in bone involves different mechanisms in the pre-
and post-menopausal microenvironment, and that it may potentially only be driven by
osteoclast activity in post-menopausal bone.
Our data are the first to demonstrate that the cellular and molecular mechanisms are
responsible for driving tumour growth differ in the pre- (sham) and post-menopausal (OVX)
bone metastasis models. We show that osteoclast-mediated mechanisms are instrumental for
the progression of disseminated tumour cells in bone only in the post-menopausal model,
and hence provide biological evidence underpinning why the benefit of adjuvant anti-
resorptive therapy reported is restricted to post-menopausal breast cancer patients in recent
clinical trials.
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Refer to Web version on PubMed Central for supplementary material.
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Statement of translational relevance
Our study addresses the surprising findings from clinical trials that addition of zoledronic
acid to standard chemotherapy and/or hormone therapy has differential effects depending
on the patients’ menopausal status, with the survival benefits being restricted to patients
with established menopause. Our study provides the first comprehensive in vivo evidence
of how the cellular mechanisms involved in initiating bone metastasis differ in the pre-
and post menopausal bone microenvironment. Our data also demonstrate a link between
menopausal status and the differential anti-tumour effects of zoledronic acid. We show
that osteoclast-mediated mechanisms are instrumental in the tumourigenic progression of
disseminated breast cancer cells in bone exclusively in the post-menopausal setting;
providing the biological evidence that support specific benefits of adjuvant anti-
resorptive therapy for post-menopausal breast cancer patients.
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Figure 1. Effects of ovariectomy on bone structure and bone turnover
(a) Bone volume 0, 1, 2, 3, 4, 5 and 8 weeks following ovariectomy. (b) Photomicrographs
of Goldners’ stained histological sections of the tibia and reconstructed μCT images at
baseline and 8 weeks following ovariectomy or sham operation. Osteoclast activity was
analysed by measuring serum levels of TRACP 5b and osteoblast activity assessed by
measuring P1NP (c) in ovariectomised mice compared with sham operated animals.
Numbers of osteoclasts and osteoblasts (d) lining the bone surface 0, 1, 2, 3, 4, 5 and 8
weeks following ovariectomy. Data shown are mean ± SEM and * represents a p value of <
0.05.
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Figure 2. Ovariectomy increases of the number of MDA-MB-231 breast cancer cell colonies in
bone
Experimental outline (a) and (b) photographs of luciferase expressing MDA-MB-231 cells
inoculated 7 days after ovariectomy or sham operation and 56 days following tumour cell
inoculation. The percentage of mice with detectable tumours and mean tumour volume ±
SEM shown as numbers of photons per second per tumour (c). Bone volume following
ovariectomy in mice injected with MDA-MB-231 cells (mean ± SEM) and uCT images
representing bone architecture (d). All data are shown for 56 days following tumour cell
inoculation and * represents a p value of < 0.05.
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Figure 3. Ovariectomy stimulates growth of established breast cancer cells in long bones of 12-
week-old immunocompromised mice
Experimental outline (a) and photographs of luciferase expressing MDA-MB-231 cells
inoculated 7 days before ovariectomy or sham operation growing in mice 49 days following
tumour cell inoculation (b). Percentage of mice with detectable tumours and mean tumour
volume ± SEM is shown as numbers of photons per second per tumour (c). Effects on bone
volume following ovariectomy in mice injected with MDA-MB-231 cells (mean ± SEM)
and μCT images representing bone architecture (d). All data are shown for 49 days
following tumour cell inoculation and * represents a p value of < 0.05.
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Figure 4. Zoledronic acid inhibits bone resorption and reduces tumour take in ovariectomised
mice
(a) Experimental outline. (b) Histogram showing mean ± SEM % of mice with detectable
bone tumours in control and zoledronic acid treated ovariectomised and sham operated mice
35 days following tumour cell inoculation. (c) Bone volume compared with trabecular
volume 28 days following ovariectomy and 31 days following zoledronic acid treatment in
mice pre-injected with MDA-MB-231 cells (mean ± SEM). (d) μCT images representing
bone architecture at the end of the experimental protocol. * represents a p value of < 0.05
compared with sham control and ** a p value of < 0.05 compared with sham control and
OVX control.
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Figure 5. Non-proliferating tumour cells are present in proximal trabecular bone of mice
without detectable metastasis
Confocal images of disseminated DiD labelled tumour cells (red cells highlighted with
yellow block arrows) that have homed to bone but not formed tumours in tibiae of
ovariectomised control mice (a), ovariectomised zoledronic acid treated mice (b), sham
control (c) and sham zoledronic acid treated animals (d).
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Table 1
Genetic alterations in mouse long bone 1 week following ovariectomy with and without
zoledronic acid treatment
Protein coded for Fold Change OVX
vs Sham
Fold Change
Sham Zol vs Sham
Fold Change
OVX Zol vs Sham
Zol
Fold Change OVX
Zol vs OVX
KitL C-kit ligand 5.33 ± 0.91* −1.34 ±1.56 4.23 ± 0.83* − 1.90 ± 0.11
Tnfsf11 Receptor activator of nuclear
factor kappa-B ligand
4.87 ± 0.58* −2.2 ± 0.12* 0.35 ± 0.97 −6.73 ± 1.26*
BGlap Osteocalcin 4.69 ± 2.39* 4.96 ± 1.54* 5.83 ± 0.49* 5.74 ± 2.04*
Ctsk Cathepsin K 3.81 ± 0.12* −3.09 ± 0.63* 0.07 ± 0.23 −6.82 ± 0.38*
Spp1 Osteopontin 3.74 ± 0.51* −2.06 ± 0.38 0.07 ± 0.44 −5.74 ± 0.52 *
Dkk1 Dickkopf 1 3.73 ± 0.69* −2.86 ± 0.62* 0.18 ± 0.49 −6.42 ± 0.33 *
Igf2 Insulin-like growth factor 2 3.71 ± 0.45* 0.36 ± 1.82 3.54 ± 1.36* −0.07 ± 0.66
MmP9 Matrix metallopeptidase 9 3.54 ± 0.41* −2.11 ± 0.22 0.24 ± 0.11 −5.40 ± 0.22*
Lif Leukemia inhibitory factor 3.36 ± 0.54* 1.06 ± 1.15 2.22 ± 0.31* − 0.36 ± 0.72
Cxcl12 Chemokine ligand 12 2.97 ± 0.73* −1.65 ± 0.86 0.30 ± 0.19 −6.23 ± 1.51 *
Dkk2 Dickkopf 2 2.96 ± 0.26* −2.60 ± 0. 42* 0.27 ± 1.02 −5.30 ± 0.42*
Sp7 Osterix 2.91 ± 0.44* 0.18 ± 0.23 2.95 ± 0.98 0.22 ± 0.09
Igf1 Insulin-like growth factor 1 2.81 ± 0.25* 0.28 ± 0.43 2.39 ± 0.26* −0.14 ± 0.19
MmP14 Matrix metallopeptidase 14
−2.77 ± 0.23* −0.89 ± 0.71 −2.50 ± 0.41* −0.61 ± 0.10
Tnf Tumour necrosis factor 2.73 ± 0.16* −2.57 ± 0.51* 0.37 ± 0.68 −4.91 ± 0.40*
Tnfrsf11b Osteoprotegrin
−2.56 ± 0.11* 2.87 ± 0.53* −0.44 ± 0.51 5.00 ± 0.72*
Dkk3 Dickkopf 3 2.46 ± 0.36* −0.58 ± 0.64 0.08 ± 0.65 −3.99 ± 0.51*
MmP2 Matrix metallopeptidase 2
−2.35 ± 0.19* 2.72 ± 0.29* −0.17 ± 0.35 4.90 ± 0.16*
Ccnd1 Cyclin D1
−2.31 ± 0.41* −4.13 ± 0.56* −0.38 ± 0.52 −4.51 ± 0.72*
Pth Parathyroid hormone 2.26 ± 0.26* 0.09 ± 0.87 −0.61 ± 0.71 −3.68 ± 1.57*
Apc5 TRAP 2.25 ± 0.22* −2.43 ± 0.25* 0.15 ± 0.26 −5.13 ± 0.25*
*
Represents a p value of < 0.05.
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